Abstract：Objective: To investigate the therapeutic effect of non bustatin combined with hydrochlorothiazide on chronic kidney disease and its effect on serum cystatin C (Cys-C) and N-terminal pro brain natriuretic peptide (NT proBNP). Methods: 80 patients with chronic kidney disease admitted to our hospital from June 2017 to June 2019 were selected for the study,they were divided into observation group (n=41) and control group (n=39) by simple random grouping. The control group was treated with hydrochlorothiazide and the observation group was treated with febuxostat on the basis of the control group. The clinical efficacy, serum cys-c, nt-probnp, urea nitrogen (BUN), serum creatinine (SCr), urinary albumin (Upro) levels and adverse reactions were compared between the two groups. Results: The total effective rate in the observation group was 85.37%, significantly higher than 64.10% in the control group (P<0.05). Before treatment, there was no significant difference in the levels of cys-c and nt-probnp between the two groups (P>0.05). After treatment, the levels of cys-c and nt-probnp in both groups decreased significantly, and the observation group was lower than the control group (P<0.05). Before treatment, there was no significant difference in renal function between the two groups (P>0.05). After treatment, the levels of BUN, SCr and Upro in both groups were significantly improved, and the levels of BUN, SCr and Upro in the observation group were lower than those in the control group (P<0.05). The total incidence of adverse reactions was 14.63% in the observation group and 20.51% in the control group, with no significant difference (P＞0.05). Conclusion: Febuxostat combined with hydrochlorothiazide has a significant effect in patients with chronic kidney disease, which can effectively improve the serum cys-c, nt-probnp and renal function of patients without increasing adverse reactions.
张素明, 叶丽萍, 程卫, 朱云. 非布司他联合氢氯噻嗪治疗慢性肾脏病的疗效及对血清Cys-C NT-proBNP的影响[J]. 河北医学, 2020, 26(5): 763-766.
ZHANG Suming, YE Liping, CHENG Wei, et al. Therapeutic Effect of Febuxostat Combined with Hydrochlorothiazide on Chronic Kidney Disease and its Efect on Serum Cys-C and NT proBNP. HeBei Med, 2020, 26(5): 763-766.
[1] 石凯峰,张宁,刘世巍,等.高磷血症致慢性肾脏病血管钙化的研究及治疗进展[J].世界中医药,2017,12(2):465~469. [2] 张鹏.探讨联合检测Cys-C、NT-proBNP、DD和AT-Ⅲ在糖尿病肾病早期诊断中的临床价值[J].中国医药指南,2018,16(11):150~151. [3] 杨俊,周雅珊,梁琼.糖尿病慢性肾脏疾病患者血清上皮衍生因子水平变化及其临床意义[J].检验医学与临床,2017,14(13):1853~1855. [4] Adeniyi A B, Laurence C E, Volmink J A, et al. Prevalence of chronic kidney disease and association with cardiovascular risk factors among teachers in cape town, south africa[J]. Clinical Kidney Journal, 2017, 10(3):363~369. [5] 上海慢性肾脏病早发现及规范化诊治与示范项目专家组,高翔,梅长林.慢性肾脏病筛查,诊断及防治指南[J].中国实用内科杂志,2017,37(1):33~39. [6] 蔡露茜,刘慧.呋塞米与氢氯噻嗪治疗慢性肾脏病合并高血压患者的临床疗效[J].中国生化药物杂志,2016,36(6):94~96. [7] 王庆文.慢性肾脏病患者降尿酸药的合理应用[J].肾脏病与透析肾移植杂志,2016,25(1):48~49. [8] 陈松,黄健,杨静,等.非布司他治疗慢性肾脏病伴高尿酸血症的临床研究[J].实用医学杂志,2016,32(3):472~474. [9] Lo C, Teede H, Fulcher G, et al. Gaps and barriers in health-care provision for comorbid diabetes and chronic kidney disease: a cross-sectional study[J]. Bmc Nephrology, 2017, 18(1):80. [10] 余明杰,王萍,张静,等.血清PTH、Cys-C联合检测在慢性肾病患者诊疗中的应用价值[J].临床输血与检验,2017,19(3):275~277. [11] 王垚,于博.别嘌醇对慢性肾脏病合并无症状高尿酸血症患者肾功能的影响[J].临床肾脏病杂志,2017,17(2):85~89.
2020, Vol. 26 
冀公网安备13080202000677号